Docetaxel/2-Hydroxypropyl β -Cyclodextrin Inclusion Complex Increases Docetaxel Solubility and Release from a Nanochannel Drug Delivery System

Curr Drug Targets. 2015;16(14):1645-9. doi: 10.2174/138945011614151119125541.


Breast cancer remains the second leading cause of cancer deaths for women in the U.S. The need for new and alternative strategies to treat this cancer is imperative. Here we show the optimization of our nanochannel delivery system (nDS) for constant and sustained delivery of docetaxel (DTX) for thetreatment of triple negative breast cancer. DTX is a highly hydrophobic drug, making it difficult to reach the therapeutic levels when released in aqueous solutions from our implantable delivery system. To overcome this challenge and test the release of DTX from nDS, we prepared DTX/2-hydroxypropyl β-cyclodextrin (DTX/HPCD) inclusion complexes in different molar ratios. The 1:10 DTX/HPCD complex achieved 5 times higher solubility than the 1:2 complex and 3 times higher in vitrorelease of DTX than with free DTX. When released in SCID/Beige mice from nanochannel system, the DTX/HPCD complex showed reduced tumor growth, comparable to the standard bolus injections of DTX, indicating that the structural stability and biological activity of DTX were retained in the complex, after its diffusion through the nanochannel system.

MeSH terms

  • 2-Hydroxypropyl-beta-cyclodextrin
  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / chemistry
  • Delayed-Action Preparations
  • Docetaxel
  • Drug Delivery Systems / methods*
  • Female
  • Humans
  • Mice
  • Mice, SCID
  • Taxoids / administration & dosage*
  • Taxoids / chemistry
  • Triple Negative Breast Neoplasms / drug therapy*
  • Xenograft Model Antitumor Assays
  • beta-Cyclodextrins / chemistry*


  • Antineoplastic Agents
  • Delayed-Action Preparations
  • Taxoids
  • beta-Cyclodextrins
  • Docetaxel
  • 2-Hydroxypropyl-beta-cyclodextrin